A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
• Male or female (sex at birth).
• For Part C: Japanese, Chinese or non-Asian participants (all self-reported):
‣ For Japanese participants: both parents of Japanese descent.
⁃ For Chinese participants: both parents of Chinese descent.
⁃ For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
• Age at the time of signing the informed consent:
∙ For Part A: 18-55 years (both inclusive)
‣ For Part B: 18-65 years (both inclusive)
‣ For Part C: 18-55 years (both inclusive).
• BMI at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator):
∙ For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive)
‣ For Part B: 30.0-50.0 kg/m\^2 (both inclusive)
‣ For Part C: 24-34.9 kg/m\^2 (both inclusive)
• Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.